Late Toxicity Is Not Increased in BRCA1/BRCA2 Mutation Carriers Undergoing Breast Radiotherapy in the United Kingdom
Purpose: To undertake the first substantial clinical study of breast radiotherapy toxicity in BRCA1 and BRCA2 mutation carriers in the United Kingdom. Experimental Design: Acute and late radiation effects were evaluated in a retrospective study of 55 BRCA1 and BRCA2 mutation carriers treated with ra...
Gespeichert in:
| Veröffentlicht in: | Clinical cancer research 2006-12, Vol.12 (23), p.7025-7032 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 7032 |
|---|---|
| container_issue | 23 |
| container_start_page | 7025 |
| container_title | Clinical cancer research |
| container_volume | 12 |
| creator | Shanley, Susan McReynolds, Kate Ardern-Jones, Audrey Ahern, Roger Fernando, Indrajit Yarnold, John Evans, Gareth Eccles, Diana Hodgson, Shirley Ashley, Sue Ashcroft, Linda Tutt, Andrew Bancroft, Elizabeth Short, Susan Gui, Gerald Barr, Lester Baildam, Andrew Howell, Anthony Royle, Gavin Pierce, Lori Easton, Douglas Eeles, Rosalind |
| description | Purpose: To undertake the first substantial clinical study of breast radiotherapy toxicity in BRCA1 and BRCA2 mutation carriers in the United Kingdom.
Experimental Design: Acute and late radiation effects were evaluated in a retrospective study of 55 BRCA1 and BRCA2 mutation carriers treated with radiotherapy for breast cancer at four centers between 1983 and 2002. Individual matching
with controls who had sporadic breast cancer was undertaken for age at diagnosis, time since completion of radiation, and
treatment variables. Detailed assessments were undertaken by one examiner. Median follow-up was 6.75 years for carriers and
7.75 years for controls. Rates of late events (rib fractures, lung fibrosis, necrosis of soft tissue/bone, and pericarditis)
as well as LENT-SOMA scores and clinical photography scores of breast size, shape, and skin telangiectasia were the primary
end points.
Results: No increase in clinically significant late toxicity was seen in the mutation carriers.
Conclusions: These data add substantial weight to the evidence that the outcomes in the treated breast from radiotherapy in women with
BRCA1 or BRCA2 mutations are comparable with those in women with sporadic breast cancer. |
| doi_str_mv | 10.1158/1078-0432.CCR-06-1244 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68215671</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>19518954</sourcerecordid><originalsourceid>FETCH-LOGICAL-c372t-320f15c12508360f1d3cec96a50a5d097e0568ebf79041ecfd0cae8d140c424c3</originalsourceid><addsrcrecordid>eNqFkU9vEzEQxS0EoqXwEUA-IXHYdsZr759juyoQEUCK2rPl2rOJUbIOtiPIt8erBHHkMn6H33sjz2PsLcI1oupuENquAlmL62FYVdBUKKR8xi5RqbaqRaOeF_2XuWCvUvoBgBJBvmQX2KJUnZCXLC9NJv4Qfnvr85EvEv8WMl9MNpJJ5Lif-N1quMWbeQr-9ZBN9mHig4nRU0z8cXIU18FPa343ezJfGedD3lA0--PsL7JQPpe0LwVzYfeavRjNNtGb83vFHj_ePwyfq-X3T4vhdlnZuhW5_AJGVBaFgq5uina1Jds3RoFRDvqWQDUdPY1tDxLJjg6soc6hBCuFtPUVe3_K3cfw80Ap651PlrZbM1E4JN10AlXT4n9B7BV2vZIFVCfQxpBSpFHvo9-ZeNQIeu5FzzfX88116UVDo-deiu_decHhaUfun-tcRAE-nICNX29--UjamslSjJTIRLspMVrUugWh6j-1NpYY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>19518954</pqid></control><display><type>article</type><title>Late Toxicity Is Not Increased in BRCA1/BRCA2 Mutation Carriers Undergoing Breast Radiotherapy in the United Kingdom</title><source>MEDLINE</source><source>American Association for Cancer Research</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Shanley, Susan ; McReynolds, Kate ; Ardern-Jones, Audrey ; Ahern, Roger ; Fernando, Indrajit ; Yarnold, John ; Evans, Gareth ; Eccles, Diana ; Hodgson, Shirley ; Ashley, Sue ; Ashcroft, Linda ; Tutt, Andrew ; Bancroft, Elizabeth ; Short, Susan ; Gui, Gerald ; Barr, Lester ; Baildam, Andrew ; Howell, Anthony ; Royle, Gavin ; Pierce, Lori ; Easton, Douglas ; Eeles, Rosalind</creator><creatorcontrib>Shanley, Susan ; McReynolds, Kate ; Ardern-Jones, Audrey ; Ahern, Roger ; Fernando, Indrajit ; Yarnold, John ; Evans, Gareth ; Eccles, Diana ; Hodgson, Shirley ; Ashley, Sue ; Ashcroft, Linda ; Tutt, Andrew ; Bancroft, Elizabeth ; Short, Susan ; Gui, Gerald ; Barr, Lester ; Baildam, Andrew ; Howell, Anthony ; Royle, Gavin ; Pierce, Lori ; Easton, Douglas ; Eeles, Rosalind ; Breast Unit of the Royal Marsden NHS Foundation Trust ; The Breast Unit of the Royal Marsden NHS Foundation Trust</creatorcontrib><description>Purpose: To undertake the first substantial clinical study of breast radiotherapy toxicity in BRCA1 and BRCA2 mutation carriers in the United Kingdom.
Experimental Design: Acute and late radiation effects were evaluated in a retrospective study of 55 BRCA1 and BRCA2 mutation carriers treated with radiotherapy for breast cancer at four centers between 1983 and 2002. Individual matching
with controls who had sporadic breast cancer was undertaken for age at diagnosis, time since completion of radiation, and
treatment variables. Detailed assessments were undertaken by one examiner. Median follow-up was 6.75 years for carriers and
7.75 years for controls. Rates of late events (rib fractures, lung fibrosis, necrosis of soft tissue/bone, and pericarditis)
as well as LENT-SOMA scores and clinical photography scores of breast size, shape, and skin telangiectasia were the primary
end points.
Results: No increase in clinically significant late toxicity was seen in the mutation carriers.
Conclusions: These data add substantial weight to the evidence that the outcomes in the treated breast from radiotherapy in women with
BRCA1 or BRCA2 mutations are comparable with those in women with sporadic breast cancer.</description><identifier>ISSN: 1078-0432</identifier><identifier>EISSN: 1557-3265</identifier><identifier>DOI: 10.1158/1078-0432.CCR-06-1244</identifier><identifier>PMID: 17145824</identifier><language>eng</language><publisher>United States: American Association for Cancer Research</publisher><subject>Adult ; Aged ; BRCA1/2 ; breast cancer ; Breast Neoplasms - diagnosis ; Breast Neoplasms - genetics ; Breast Neoplasms - therapy ; Case-Control Studies ; Female ; Follow-Up Studies ; Genes, BRCA1 ; Genes, BRCA2 ; Germ-Line Mutation ; Heterozygote ; Humans ; late toxicity ; Middle Aged ; mutation carriers ; Neoplasm Staging ; Radiotherapy ; Retrospective Studies ; Treatment Outcome ; United Kingdom - epidemiology</subject><ispartof>Clinical cancer research, 2006-12, Vol.12 (23), p.7025-7032</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c372t-320f15c12508360f1d3cec96a50a5d097e0568ebf79041ecfd0cae8d140c424c3</citedby><cites>FETCH-LOGICAL-c372t-320f15c12508360f1d3cec96a50a5d097e0568ebf79041ecfd0cae8d140c424c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,3343,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17145824$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shanley, Susan</creatorcontrib><creatorcontrib>McReynolds, Kate</creatorcontrib><creatorcontrib>Ardern-Jones, Audrey</creatorcontrib><creatorcontrib>Ahern, Roger</creatorcontrib><creatorcontrib>Fernando, Indrajit</creatorcontrib><creatorcontrib>Yarnold, John</creatorcontrib><creatorcontrib>Evans, Gareth</creatorcontrib><creatorcontrib>Eccles, Diana</creatorcontrib><creatorcontrib>Hodgson, Shirley</creatorcontrib><creatorcontrib>Ashley, Sue</creatorcontrib><creatorcontrib>Ashcroft, Linda</creatorcontrib><creatorcontrib>Tutt, Andrew</creatorcontrib><creatorcontrib>Bancroft, Elizabeth</creatorcontrib><creatorcontrib>Short, Susan</creatorcontrib><creatorcontrib>Gui, Gerald</creatorcontrib><creatorcontrib>Barr, Lester</creatorcontrib><creatorcontrib>Baildam, Andrew</creatorcontrib><creatorcontrib>Howell, Anthony</creatorcontrib><creatorcontrib>Royle, Gavin</creatorcontrib><creatorcontrib>Pierce, Lori</creatorcontrib><creatorcontrib>Easton, Douglas</creatorcontrib><creatorcontrib>Eeles, Rosalind</creatorcontrib><creatorcontrib>Breast Unit of the Royal Marsden NHS Foundation Trust</creatorcontrib><creatorcontrib>The Breast Unit of the Royal Marsden NHS Foundation Trust</creatorcontrib><title>Late Toxicity Is Not Increased in BRCA1/BRCA2 Mutation Carriers Undergoing Breast Radiotherapy in the United Kingdom</title><title>Clinical cancer research</title><addtitle>Clin Cancer Res</addtitle><description>Purpose: To undertake the first substantial clinical study of breast radiotherapy toxicity in BRCA1 and BRCA2 mutation carriers in the United Kingdom.
Experimental Design: Acute and late radiation effects were evaluated in a retrospective study of 55 BRCA1 and BRCA2 mutation carriers treated with radiotherapy for breast cancer at four centers between 1983 and 2002. Individual matching
with controls who had sporadic breast cancer was undertaken for age at diagnosis, time since completion of radiation, and
treatment variables. Detailed assessments were undertaken by one examiner. Median follow-up was 6.75 years for carriers and
7.75 years for controls. Rates of late events (rib fractures, lung fibrosis, necrosis of soft tissue/bone, and pericarditis)
as well as LENT-SOMA scores and clinical photography scores of breast size, shape, and skin telangiectasia were the primary
end points.
Results: No increase in clinically significant late toxicity was seen in the mutation carriers.
Conclusions: These data add substantial weight to the evidence that the outcomes in the treated breast from radiotherapy in women with
BRCA1 or BRCA2 mutations are comparable with those in women with sporadic breast cancer.</description><subject>Adult</subject><subject>Aged</subject><subject>BRCA1/2</subject><subject>breast cancer</subject><subject>Breast Neoplasms - diagnosis</subject><subject>Breast Neoplasms - genetics</subject><subject>Breast Neoplasms - therapy</subject><subject>Case-Control Studies</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Genes, BRCA1</subject><subject>Genes, BRCA2</subject><subject>Germ-Line Mutation</subject><subject>Heterozygote</subject><subject>Humans</subject><subject>late toxicity</subject><subject>Middle Aged</subject><subject>mutation carriers</subject><subject>Neoplasm Staging</subject><subject>Radiotherapy</subject><subject>Retrospective Studies</subject><subject>Treatment Outcome</subject><subject>United Kingdom - epidemiology</subject><issn>1078-0432</issn><issn>1557-3265</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU9vEzEQxS0EoqXwEUA-IXHYdsZr759juyoQEUCK2rPl2rOJUbIOtiPIt8erBHHkMn6H33sjz2PsLcI1oupuENquAlmL62FYVdBUKKR8xi5RqbaqRaOeF_2XuWCvUvoBgBJBvmQX2KJUnZCXLC9NJv4Qfnvr85EvEv8WMl9MNpJJ5Lif-N1quMWbeQr-9ZBN9mHig4nRU0z8cXIU18FPa343ezJfGedD3lA0--PsL7JQPpe0LwVzYfeavRjNNtGb83vFHj_ePwyfq-X3T4vhdlnZuhW5_AJGVBaFgq5uina1Jds3RoFRDvqWQDUdPY1tDxLJjg6soc6hBCuFtPUVe3_K3cfw80Ap651PlrZbM1E4JN10AlXT4n9B7BV2vZIFVCfQxpBSpFHvo9-ZeNQIeu5FzzfX88116UVDo-deiu_decHhaUfun-tcRAE-nICNX29--UjamslSjJTIRLspMVrUugWh6j-1NpYY</recordid><startdate>20061201</startdate><enddate>20061201</enddate><creator>Shanley, Susan</creator><creator>McReynolds, Kate</creator><creator>Ardern-Jones, Audrey</creator><creator>Ahern, Roger</creator><creator>Fernando, Indrajit</creator><creator>Yarnold, John</creator><creator>Evans, Gareth</creator><creator>Eccles, Diana</creator><creator>Hodgson, Shirley</creator><creator>Ashley, Sue</creator><creator>Ashcroft, Linda</creator><creator>Tutt, Andrew</creator><creator>Bancroft, Elizabeth</creator><creator>Short, Susan</creator><creator>Gui, Gerald</creator><creator>Barr, Lester</creator><creator>Baildam, Andrew</creator><creator>Howell, Anthony</creator><creator>Royle, Gavin</creator><creator>Pierce, Lori</creator><creator>Easton, Douglas</creator><creator>Eeles, Rosalind</creator><general>American Association for Cancer Research</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>7U7</scope><scope>C1K</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20061201</creationdate><title>Late Toxicity Is Not Increased in BRCA1/BRCA2 Mutation Carriers Undergoing Breast Radiotherapy in the United Kingdom</title><author>Shanley, Susan ; McReynolds, Kate ; Ardern-Jones, Audrey ; Ahern, Roger ; Fernando, Indrajit ; Yarnold, John ; Evans, Gareth ; Eccles, Diana ; Hodgson, Shirley ; Ashley, Sue ; Ashcroft, Linda ; Tutt, Andrew ; Bancroft, Elizabeth ; Short, Susan ; Gui, Gerald ; Barr, Lester ; Baildam, Andrew ; Howell, Anthony ; Royle, Gavin ; Pierce, Lori ; Easton, Douglas ; Eeles, Rosalind</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c372t-320f15c12508360f1d3cec96a50a5d097e0568ebf79041ecfd0cae8d140c424c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Adult</topic><topic>Aged</topic><topic>BRCA1/2</topic><topic>breast cancer</topic><topic>Breast Neoplasms - diagnosis</topic><topic>Breast Neoplasms - genetics</topic><topic>Breast Neoplasms - therapy</topic><topic>Case-Control Studies</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Genes, BRCA1</topic><topic>Genes, BRCA2</topic><topic>Germ-Line Mutation</topic><topic>Heterozygote</topic><topic>Humans</topic><topic>late toxicity</topic><topic>Middle Aged</topic><topic>mutation carriers</topic><topic>Neoplasm Staging</topic><topic>Radiotherapy</topic><topic>Retrospective Studies</topic><topic>Treatment Outcome</topic><topic>United Kingdom - epidemiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shanley, Susan</creatorcontrib><creatorcontrib>McReynolds, Kate</creatorcontrib><creatorcontrib>Ardern-Jones, Audrey</creatorcontrib><creatorcontrib>Ahern, Roger</creatorcontrib><creatorcontrib>Fernando, Indrajit</creatorcontrib><creatorcontrib>Yarnold, John</creatorcontrib><creatorcontrib>Evans, Gareth</creatorcontrib><creatorcontrib>Eccles, Diana</creatorcontrib><creatorcontrib>Hodgson, Shirley</creatorcontrib><creatorcontrib>Ashley, Sue</creatorcontrib><creatorcontrib>Ashcroft, Linda</creatorcontrib><creatorcontrib>Tutt, Andrew</creatorcontrib><creatorcontrib>Bancroft, Elizabeth</creatorcontrib><creatorcontrib>Short, Susan</creatorcontrib><creatorcontrib>Gui, Gerald</creatorcontrib><creatorcontrib>Barr, Lester</creatorcontrib><creatorcontrib>Baildam, Andrew</creatorcontrib><creatorcontrib>Howell, Anthony</creatorcontrib><creatorcontrib>Royle, Gavin</creatorcontrib><creatorcontrib>Pierce, Lori</creatorcontrib><creatorcontrib>Easton, Douglas</creatorcontrib><creatorcontrib>Eeles, Rosalind</creatorcontrib><creatorcontrib>Breast Unit of the Royal Marsden NHS Foundation Trust</creatorcontrib><creatorcontrib>The Breast Unit of the Royal Marsden NHS Foundation Trust</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical cancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shanley, Susan</au><au>McReynolds, Kate</au><au>Ardern-Jones, Audrey</au><au>Ahern, Roger</au><au>Fernando, Indrajit</au><au>Yarnold, John</au><au>Evans, Gareth</au><au>Eccles, Diana</au><au>Hodgson, Shirley</au><au>Ashley, Sue</au><au>Ashcroft, Linda</au><au>Tutt, Andrew</au><au>Bancroft, Elizabeth</au><au>Short, Susan</au><au>Gui, Gerald</au><au>Barr, Lester</au><au>Baildam, Andrew</au><au>Howell, Anthony</au><au>Royle, Gavin</au><au>Pierce, Lori</au><au>Easton, Douglas</au><au>Eeles, Rosalind</au><aucorp>Breast Unit of the Royal Marsden NHS Foundation Trust</aucorp><aucorp>The Breast Unit of the Royal Marsden NHS Foundation Trust</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Late Toxicity Is Not Increased in BRCA1/BRCA2 Mutation Carriers Undergoing Breast Radiotherapy in the United Kingdom</atitle><jtitle>Clinical cancer research</jtitle><addtitle>Clin Cancer Res</addtitle><date>2006-12-01</date><risdate>2006</risdate><volume>12</volume><issue>23</issue><spage>7025</spage><epage>7032</epage><pages>7025-7032</pages><issn>1078-0432</issn><eissn>1557-3265</eissn><abstract>Purpose: To undertake the first substantial clinical study of breast radiotherapy toxicity in BRCA1 and BRCA2 mutation carriers in the United Kingdom.
Experimental Design: Acute and late radiation effects were evaluated in a retrospective study of 55 BRCA1 and BRCA2 mutation carriers treated with radiotherapy for breast cancer at four centers between 1983 and 2002. Individual matching
with controls who had sporadic breast cancer was undertaken for age at diagnosis, time since completion of radiation, and
treatment variables. Detailed assessments were undertaken by one examiner. Median follow-up was 6.75 years for carriers and
7.75 years for controls. Rates of late events (rib fractures, lung fibrosis, necrosis of soft tissue/bone, and pericarditis)
as well as LENT-SOMA scores and clinical photography scores of breast size, shape, and skin telangiectasia were the primary
end points.
Results: No increase in clinically significant late toxicity was seen in the mutation carriers.
Conclusions: These data add substantial weight to the evidence that the outcomes in the treated breast from radiotherapy in women with
BRCA1 or BRCA2 mutations are comparable with those in women with sporadic breast cancer.</abstract><cop>United States</cop><pub>American Association for Cancer Research</pub><pmid>17145824</pmid><doi>10.1158/1078-0432.CCR-06-1244</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1078-0432 |
| ispartof | Clinical cancer research, 2006-12, Vol.12 (23), p.7025-7032 |
| issn | 1078-0432 1557-3265 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68215671 |
| source | MEDLINE; American Association for Cancer Research; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Adult Aged BRCA1/2 breast cancer Breast Neoplasms - diagnosis Breast Neoplasms - genetics Breast Neoplasms - therapy Case-Control Studies Female Follow-Up Studies Genes, BRCA1 Genes, BRCA2 Germ-Line Mutation Heterozygote Humans late toxicity Middle Aged mutation carriers Neoplasm Staging Radiotherapy Retrospective Studies Treatment Outcome United Kingdom - epidemiology |
| title | Late Toxicity Is Not Increased in BRCA1/BRCA2 Mutation Carriers Undergoing Breast Radiotherapy in the United Kingdom |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T07%3A57%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Late%20Toxicity%20Is%20Not%20Increased%20in%20BRCA1/BRCA2%20Mutation%20Carriers%20Undergoing%20Breast%20Radiotherapy%20in%20the%20United%20Kingdom&rft.jtitle=Clinical%20cancer%20research&rft.au=Shanley,%20Susan&rft.aucorp=Breast%20Unit%20of%20the%20Royal%20Marsden%20NHS%20Foundation%20Trust&rft.date=2006-12-01&rft.volume=12&rft.issue=23&rft.spage=7025&rft.epage=7032&rft.pages=7025-7032&rft.issn=1078-0432&rft.eissn=1557-3265&rft_id=info:doi/10.1158/1078-0432.CCR-06-1244&rft_dat=%3Cproquest_cross%3E19518954%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=19518954&rft_id=info:pmid/17145824&rfr_iscdi=true |